156 related articles for article (PubMed ID: 38100900)
1. Continuing versus tapering low-dose glucocorticoids in patients with rheumatoid arthritis and systemic lupus erythematosus in states of low disease activity or remission: A systematic review and meta-analysis of randomised trials.
Palmowski A; Pankow A; Terziyska K; Nielsen SM; Christensen R; Bliddal H; Boyadzhieva Z; Buttgereit F
Semin Arthritis Rheum; 2024 Feb; 64():152349. PubMed ID: 38100900
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy associated with long-term low-dose glucocorticoids in rheumatoid arthritis: a systematic review and meta-analysis.
Palmowski A; Nielsen SM; Boyadzhieva Z; Schneider A; Pankow A; Hartman L; Da Silva JAP; Kirwan J; Wassenberg S; Dejaco C; Christensen R; Boers M; Buttgereit F
Rheumatology (Oxford); 2023 Aug; 62(8):2652-2660. PubMed ID: 36810945
[TBL] [Abstract][Full Text] [Related]
3. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
Burmester GR; Buttgereit F; Bernasconi C; Álvaro-Gracia JM; Castro N; Dougados M; Gabay C; van Laar JM; Nebesky JM; Pethoe-Schramm A; Salvarani C; Donath MY; John MR;
Lancet; 2020 Jul; 396(10246):267-276. PubMed ID: 32711802
[TBL] [Abstract][Full Text] [Related]
4. How to taper glucocorticoids in inflammatory rheumatic diseases? A narrative review of novel evidence in rheumatoid arthritis, systemic lupus erythematosus, and giant cell arteritis.
Buttgereit F; Palmowski A
Joint Bone Spine; 2022 Jan; 89(1):105285. PubMed ID: 34601110
[TBL] [Abstract][Full Text] [Related]
5. Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
Verhoef LM; van den Bemt BJ; van der Maas A; Vriezekolk JE; Hulscher ME; van den Hoogen FH; Jacobs WC; van Herwaarden N; den Broeder AA
Cochrane Database Syst Rev; 2019 May; 5(5):CD010455. PubMed ID: 31125448
[TBL] [Abstract][Full Text] [Related]
6. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
7. Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial.
Almayali AAH; Boers M; Hartman L; Opris D; Bos R; Kok MR; Da Silva JA; Griep E; Klaasen R; Allaart CF; Baudoin P; Raterman HG; Szekanecz Z; Buttgereit F; Masaryk P; Lems W; Smulders Y; Cutolo M; Ter Wee MM
Ann Rheum Dis; 2023 Oct; 82(10):1307-1314. PubMed ID: 37541762
[TBL] [Abstract][Full Text] [Related]
8. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
[TBL] [Abstract][Full Text] [Related]
9. Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study.
Cho J; Shen L; Huq M; Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Hamijoyo L; Luo SF; Wu YJ; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake D; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Navarra SV; Lau CS; Hoi A; Morand EF; Nikpour M; Lateef A;
Lancet Rheumatol; 2023 Oct; 5(10):e584-e593. PubMed ID: 38251484
[TBL] [Abstract][Full Text] [Related]
10. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study.
Emery P; Burmester GR; Naredo E; Sinigaglia L; Lagunes I; Koenigsbauer F; Conaghan PG
Ann Rheum Dis; 2020 Aug; 79(8):1023-1030. PubMed ID: 32404343
[TBL] [Abstract][Full Text] [Related]
12. Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs).
Adami G; Fassio A; Rossini M; Bertelle D; Pistillo F; Benini C; Viapiana O; Gatti D
RMD Open; 2023 Jan; 9(1):. PubMed ID: 36599630
[TBL] [Abstract][Full Text] [Related]
13. Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review.
Kuijper TM; Lamers-Karnebeek FB; Jacobs JW; Hazes JM; Luime JJ
J Rheumatol; 2015 Nov; 42(11):2012-22. PubMed ID: 26428204
[TBL] [Abstract][Full Text] [Related]
14. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
[TBL] [Abstract][Full Text] [Related]
15. Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial.
Hartman L; Rasch LA; Klausch T; Bijlsma HWJ; Christensen R; Smulders YM; Ralston SH; Buttgereit F; Cutolo M; Da Silva JAP; Opris D; Rovenský J; Szamosi S; Middelink LM; Lems WF; Boers M
Trials; 2018 Jan; 19(1):67. PubMed ID: 29370811
[TBL] [Abstract][Full Text] [Related]
16. A comparison of rheumatoid arthritis and systemic lupus erythematosus trial design: a commentary on ways to improve the number of positive trials in SLE.
Miles A; Pope JE
Clin Exp Rheumatol; 2015; 33(5):671-80. PubMed ID: 26315693
[TBL] [Abstract][Full Text] [Related]
17. Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib.
Spinelli FR; Garufi C; Mancuso S; Ceccarelli F; Truglia S; Conti F
Sci Rep; 2023 Sep; 13(1):15537. PubMed ID: 37730835
[TBL] [Abstract][Full Text] [Related]
18. Conventional versus Rapid Glucocorticoid Tapering in Severe Systemic Lupus Erythematosus Patients: A Non-Blind, Randomized Controlled Trial.
Abe Y; Fujibayashi K; Nishizaki Y; Yanagisawa N; Nojiri S; Kon T; Tada K; Yamaji K; Tamura N
Acta Med Okayama; 2020 Apr; 74(2):179-183. PubMed ID: 32341595
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real-world GULP prospective observational study.
Floris A; Chessa E; Sebastiani GD; Prevete I; Iannone F; Coladonato L; Govoni M; Bortoluzzi A; Mosca M; Tani C; Doria A; Iaccarino L; Franceschini F; Fredi M; Conti F; Spinelli FR; Bellisai F; D'Alessandro R; Zanetti A; Carrara G; Scirè CA; Cauli A; Piga M;
RMD Open; 2022 Dec; 8(2):. PubMed ID: 36581383
[TBL] [Abstract][Full Text] [Related]
20. A real-world 2-year prospective study of medication tapering in patients with well-controlled rheumatoid arthritis within the rheumatoid arthritis medication tapering (RHEUMTAP) cohort.
Tageldin M; Wilson N; Yin Y; Sharma TS
Rheumatology (Oxford); 2023 Oct; 62(Suppl_4):iv8-iv13. PubMed ID: 37855679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
